文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

激活剂还是抑制剂?GSK-3 作为一个新的药物靶点。

Activator or inhibitor? GSK-3 as a new drug target.

机构信息

Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

出版信息

Biochem Pharmacol. 2013 Jul 15;86(2):191-9. doi: 10.1016/j.bcp.2013.04.022. Epub 2013 May 2.


DOI:10.1016/j.bcp.2013.04.022
PMID:23643839
Abstract

Glycogen synthase kinase-3 (GSK-3) is a cytoplasmic serine/threonine protein kinase that phosphorylates and inhibits glycogen synthase, thereby inhibiting glycogen synthesis from glucose. However, this serine/threonine kinase is now known to regulate numerous cellular processes through a number of signaling pathways important for cell proliferation, stem cell renewal, apoptosis and development. Because of these diverse roles, malfunction of this kinase is also known to be involved in the pathogenesis of human diseases, such as nervous system disorders, diabetes, bone formation, inflammation, cancer and heart failure. Therefore, GSK-3 is recognized as an attractive target for the development of new drugs. The present review summarizes the roles of GSK-3 in the insulin, Wnt/β-catenin and hedgehog signaling pathways including the regulation of their activities. The roles of GSK-3 in the development of human diseases within the context of its participation in various signaling pathways are also summarized. Finally, the possibility of new drug development targeting this kinase is discussed with recent information about inhibitors and activators of GSK-3.

摘要

糖原合酶激酶-3(GSK-3)是一种细胞质丝氨酸/苏氨酸蛋白激酶,可磷酸化并抑制糖原合酶,从而抑制葡萄糖向糖原的合成。然而,这种丝氨酸/苏氨酸激酶现在已知通过许多对细胞增殖、干细胞更新、细胞凋亡和发育很重要的信号通路来调节许多细胞过程。由于这些不同的作用,这种激酶的功能障碍也与人类疾病的发病机制有关,如神经系统疾病、糖尿病、骨形成、炎症、癌症和心力衰竭。因此,GSK-3 被认为是开发新药的有吸引力的靶标。本综述总结了 GSK-3 在胰岛素、Wnt/β-catenin 和 hedgehog 信号通路中的作用,包括对它们活性的调节。还总结了 GSK-3 在其参与各种信号通路的人类疾病发展中的作用。最后,根据 GSK-3 的抑制剂和激活剂的最新信息,讨论了针对这种激酶的新药开发的可能性。

相似文献

[1]
Activator or inhibitor? GSK-3 as a new drug target.

Biochem Pharmacol. 2013-5-2

[2]
Roles of Glycogen Synthase Kinase-3 (GSK-3) in Cardiac Development and Heart Disease.

J UOEH. 2018

[3]
[A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].

Yao Xue Xue Bao. 2007-12

[4]
Pharmacological inhibitors of glycogen synthase kinase 3.

Trends Pharmacol Sci. 2004-9

[5]
Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.

Biochim Biophys Acta. 2016-12

[6]
Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.

Pharmacol Res. 2015-7

[7]
Glycogen synthase kinase 3 in Wnt signaling pathway and cancer.

IUBMB Life. 2015-12

[8]
Pancreastatin, a chromogranin-A-derived peptide, inhibits insulin-stimulated glycogen synthesis by activating GSK-3 in rat adipocytes.

Biochem Biophys Res Commun. 2001-11-23

[9]
Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.

Curr Opin Drug Discov Devel. 2008-7

[10]
Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation.

Med Res Rev. 2002-7

引用本文的文献

[1]
Amelioration of Liver Fibrosis via In Situ Hepatic Stellate Cell Conversion Through Co-Inhibition of TGF-β and GSK-3 Signalling.

Liver Int. 2025-7

[2]
Inhibition of GSK-3β Restores Differentiation Potential of Late-Passage Mesenchymal Stem Cells.

Pharmaceuticals (Basel). 2025-3-28

[3]
HOGA1 Suppresses Renal Cell Carcinoma Growth via Inhibiting the Wnt/β-Catenin Signalling Pathway.

J Cell Mol Med. 2025-3

[4]
Wnt/β-catenin signaling pathway: proteins' roles in osteoporosis and cancer diseases and the regulatory effects of natural compounds on osteoporosis.

Mol Med. 2024-10-28

[5]
Pharmacology of Aging: as a Tool to Validate Drug Targets for Healthy Lifespan.

Aging Biol. 2024-9-13

[6]
The role of chromatin modulator DPY30 in glucose metabolism of colorectal cancer cells.

Transl Cancer Res. 2024-8-31

[7]
Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway.

Front Cell Dev Biol. 2024-8-2

[8]
Synthesis and preliminary evaluation of novel PET probes for GSK-3 imaging.

Sci Rep. 2024-7-10

[9]
Berberine improves cognitive impairment by alleviating brain atrophy and promoting white matter reorganization in diabetic db/db mice: a magnetic resonance imaging-based study.

Metab Brain Dis. 2024-6

[10]
A novel GSK3β inhibitor 5n attenuates acute kidney injury.

Heliyon. 2024-4-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索